211 related articles for article (PubMed ID: 26369630)
21. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
22. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.
Allen JD; Jackson SC; Schinkel AH
Cancer Res; 2002 Apr; 62(8):2294-9. PubMed ID: 11956086
[TBL] [Abstract][Full Text] [Related]
23. Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1).
Matsunaga S; Asano T; Tsutsuda-Asano A; Fukunaga Y
Cancer Chemother Pharmacol; 2006 Sep; 58(3):348-53. PubMed ID: 16331495
[TBL] [Abstract][Full Text] [Related]
24. Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2016 Aug; 29(8):1270-8. PubMed ID: 27420111
[TBL] [Abstract][Full Text] [Related]
25. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
26. Development of taxane-containing chemotherapy of doxorubicin-resistant diffuse large B-cell lymphoma.
Wu L; Wang J; Li Y; Zuo L; Zhang Z; Ouyang J; Fan J; Li H
Anticancer Drugs; 2014 Aug; 25(7):826-31. PubMed ID: 24423982
[TBL] [Abstract][Full Text] [Related]
27. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.
van Wijngaarden J; van Beek E; van Rossum G; van der Bent C; Hoekman K; van der Pluijm G; van der Pol MA; Broxterman HJ; van Hinsbergh VW; Löwik CW
Eur J Cancer; 2007 Jan; 43(2):433-42. PubMed ID: 17097285
[TBL] [Abstract][Full Text] [Related]
28. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
29. Characterization of three B-cell lymphoma cell lines from chemotherapy resistant patients with respect to in vitro sensitivity to 21 antitumor agents, ABC-transporter expression and cellular redox status.
Bracht K; Kiefer T; Dölken G; Bednarski PJ
J Cancer Res Clin Oncol; 2007 Dec; 133(12):957-67. PubMed ID: 17562080
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of doxorubicin-induced apoptosis and differentiation by indomethacin in K-562 leukemia cells.
Cipák L; Paulíková H; Novotný L; Jarosová M; Rauko P
Neoplasma; 2004; 51(3):188-92. PubMed ID: 15254671
[TBL] [Abstract][Full Text] [Related]
31. Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.
Trendowski M; Christen TD; Acquafondata C; Fondy TP
BMC Cancer; 2015 Sep; 15():632. PubMed ID: 26357852
[TBL] [Abstract][Full Text] [Related]
32. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
33. Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin.
Song JH; Kim SH; Kim HJ; Hwang SY; Kim TS
Int J Oncol; 2008 Apr; 32(4):931-6. PubMed ID: 18360721
[TBL] [Abstract][Full Text] [Related]
34. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration.
Chapuy B; Koch R; Radunski U; Corsham S; Cheong N; Inagaki N; Ban N; Wenzel D; Reinhardt D; Zapf A; Schweyer S; Kosari F; Klapper W; Truemper L; Wulf GG
Leukemia; 2008 Aug; 22(8):1576-86. PubMed ID: 18463677
[TBL] [Abstract][Full Text] [Related]
35. Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.
Hembruff SL; Laberge ML; Villeneuve DJ; Guo B; Veitch Z; Cecchetto M; Parissenti AM
BMC Cancer; 2008 Nov; 8():318. PubMed ID: 18980695
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin Expands in Vivo Secretion of Circulating Exosome in Mice.
Emam SE; Ando H; Abu Lila AS; Kobayashi S; Shimizu T; Okuhira K; Ishima Y; Ishida T
Biol Pharm Bull; 2018; 41(7):1078-1083. PubMed ID: 29962402
[TBL] [Abstract][Full Text] [Related]
37. Enhanced cytotoxicity and nuclear accumulation of doxorubicin-loaded nanospheres in human breast cancer MCF7 cells expressing MRP1.
Aouali N; Morjani H; Trussardi A; Soma E; Giroux B; Manfait M
Int J Oncol; 2003 Oct; 23(4):1195-201. PubMed ID: 12964004
[TBL] [Abstract][Full Text] [Related]
38. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
39. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Wu T; Chen Z; To KKW; Fang X; Wang F; Cheng B; Fu L
Biochem Pharmacol; 2017 Jan; 124():29-42. PubMed ID: 27816545
[TBL] [Abstract][Full Text] [Related]
40. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
